TY - JOUR
T1 - Inflammatory Bowel Disease-Environmental Modification and Genetic Determinants
AU - Kugathasan, Subra
AU - Amre, Devendra
PY - 2006/8
Y1 - 2006/8
N2 - Complex disease such as IBD is controlled by multiple risk factors that evolve and interact with each other In a genetically susceptible host, there are multiple processing steps controlled by the host and the environment, from environmental exposure to the clinical and biological expression of IBD-related phenotypes. It should be obvious to most people that if new genetic discoveries are to attain their potential promise in IBD, the barriers to relax the assumptions of genotype-by-environment interactions need immediate attention. The first design issue in studying a complex disorder such as IBD is to identify and characterize the right population. Investigators should recognize this problem rather than simply work with convenient samples. For various reasons, children with newly diagnosed IBD (incident cases) are suited ideally to carry out such investigations. Technical advances of the HapMap project and the promise of whole-genome association scans have been impressive, driving down the cost of SNP genotyping while driving up the quality and completeness of the data to a degree far exceeding initial expectations. There is no single optimal design that will identify genetic and environmental factors that contribute to IBD risk most efficiently. Disease-oriented investigators who think that just by genotyping their cohorts they will produce a clean genomic solution to identifying genetic risks have been misled. The pathogenesis of IBD almost certainly is mediated by a network of effects, meaning that neither genetic nor environmental agents are separate causes of the disease state, but instead their interactions determine the risk. Investigators aimed at clarifying these interactions ultimately will lead to a clearer understanding of the underlying mechanisms of IBD, which will provide insight for improved prevention and treatment.
AB - Complex disease such as IBD is controlled by multiple risk factors that evolve and interact with each other In a genetically susceptible host, there are multiple processing steps controlled by the host and the environment, from environmental exposure to the clinical and biological expression of IBD-related phenotypes. It should be obvious to most people that if new genetic discoveries are to attain their potential promise in IBD, the barriers to relax the assumptions of genotype-by-environment interactions need immediate attention. The first design issue in studying a complex disorder such as IBD is to identify and characterize the right population. Investigators should recognize this problem rather than simply work with convenient samples. For various reasons, children with newly diagnosed IBD (incident cases) are suited ideally to carry out such investigations. Technical advances of the HapMap project and the promise of whole-genome association scans have been impressive, driving down the cost of SNP genotyping while driving up the quality and completeness of the data to a degree far exceeding initial expectations. There is no single optimal design that will identify genetic and environmental factors that contribute to IBD risk most efficiently. Disease-oriented investigators who think that just by genotyping their cohorts they will produce a clean genomic solution to identifying genetic risks have been misled. The pathogenesis of IBD almost certainly is mediated by a network of effects, meaning that neither genetic nor environmental agents are separate causes of the disease state, but instead their interactions determine the risk. Investigators aimed at clarifying these interactions ultimately will lead to a clearer understanding of the underlying mechanisms of IBD, which will provide insight for improved prevention and treatment.
UR - http://www.scopus.com/inward/record.url?scp=33746339202&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746339202&partnerID=8YFLogxK
U2 - 10.1016/j.pcl.2006.05.009
DO - 10.1016/j.pcl.2006.05.009
M3 - Review article
C2 - 16873002
AN - SCOPUS:33746339202
VL - 53
SP - 727
EP - 749
JO - Pediatric Clinics of North America
JF - Pediatric Clinics of North America
SN - 0031-3955
IS - 4
ER -